$QURE
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Healthcare
Sector
Biotechnology
Industry
Matthew Craig Kapusta
CEO
209
Employees
$41.81
Current Price
$1.50B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 4 | $2,375,630.23 | 51,167 | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 3 | 7 | $4,214,001.79 | 88,013 | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 11 | 32 | $15,786,211.24 | 364,502 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 11 | 35 | $16,993,087.69 | 412,147 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 11 | 35 | $16,993,087.69 | 412,147 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Jun 30, 2026 | Abi-Saab Walid Chief Medical Officer | Sale | 10,000 | $46.46 | $464,600.00 | View Details |
| Jun 30, 2026 | Abi-Saab Walid Chief Medical Officer | Sale | 20,000 | $46.40 | $928,000.00 | View Details |
| Jun 30, 2026 | Kaye Jack Director | Sale | 4,107 | $46.49 | $190,934.43 | View Details |
| Jun 30, 2026 | Kaye Jack Director | Sale | 17,060 | $46.43 | $792,095.80 | View Details |
| Jun 26, 2026 | Abi-Saab Walid Chief Medical Officer | Sale | 1,434 | $46.86 | $67,197.24 | View Details |
| Jun 25, 2026 | Kapusta Matthew C Director | Sale | 28,716 | $50.02 | $1,436,374.32 | View Details |
| Jun 24, 2026 | Kapusta Matthew C Director | Sale | 6,696 | $50.00 | $334,800.00 | View Details |
| Jun 17, 2026 | Kapusta Matthew C Director | Sale | 32,581 | $45.02 | $1,466,796.62 | View Details |
| Jun 17, 2026 | Kapusta Matthew C Director | Sale | 33,334 | $45.01 | $1,500,363.34 | View Details |
| Jun 17, 2026 | Kapusta Matthew C Director | Sale | 23,977 | $42.61 | $1,021,659.97 | View Details |
| Jun 18, 2026 | Kapusta Matthew C Director | Sale | 4,656 | $50.00 | $232,800.00 | View Details |
| Jun 17, 2026 | Kapusta Matthew C Director | Sale | 6,023 | $43.70 | $263,205.10 | View Details |
| Jun 17, 2026 | Kapusta Matthew C Director | Sale | 56,929 | $43.43 | $2,472,426.47 | View Details |
| Jun 18, 2026 | Kapusta Matthew C Director | Sale | 37,015 | $50.00 | $1,850,750.00 | View Details |
| Jun 17, 2026 | Kapusta Matthew C Director | Sale | 11,585 | $48.65 | $563,610.25 | View Details |
| Jun 17, 2026 | Balachandran Madhavan Director | Sale | 5,295 | $47.08 | $249,288.60 | View Details |
| Jun 17, 2026 | Balachandran Madhavan Director | Sale | 4,700 | $43.66 | $205,202.00 | View Details |
| Jun 17, 2026 | Balachandran Madhavan Director | Sale | 1,690 | $42.60 | $71,994.00 | View Details |
| Jun 17, 2026 | Kaye Jack Director | Sale | 5,295 | $42.57 | $225,408.15 | View Details |
| Jun 15, 2026 | Balachandran Madhavan Director | Sale | 10,000 | $27.85 | $278,500.00 | View Details |
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
No earnings data in the last 3 months. Sign up free to see 12 months of history.